Trial Profile
A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs TOL 463 (Primary)
- Indications Bacterial vaginosis; Vulvovaginal candidiasis
- Focus Therapeutic Use
- 31 Aug 2018 Results assessing the safety and efficacy of TOL-463, published in the Clinical Infectious Diseases.
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 18 May 2017 Planned primary completion date changed from 1 Jan 2017 to 10 Jun 2017.